Kevin B Kim Selected Research

AZD 6244

10/2017	Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
10/2017	A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
1/2017	A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
3/2014	Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.
7/2013	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
2/2013	Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
4/2012	Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kevin B Kim Research Topics

Disease

90	Melanoma (Melanoma, Malignant) 04/2024 - 04/2004
48	Neoplasms (Cancer) 04/2024 - 01/2002
16	Neoplasm Metastasis (Metastasis) 04/2024 - 12/2004
9	Disease Progression 01/2023 - 08/2009
8	Brain Neoplasms (Brain Tumor) 01/2022 - 12/2010
4	Uveal melanoma 12/2023 - 12/2010
4	Exanthema (Rash) 12/2023 - 03/2014
4	Fever (Fevers) 12/2023 - 11/2012
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 07/2014 - 09/2013
3	Thrombocytopenia (Thrombopenia) 01/2019 - 02/2012
3	Neutropenia 10/2017 - 07/2013
3	Keratoacanthoma 07/2014 - 09/2013
2	Nausea 01/2022 - 07/2013
2	Diarrhea 01/2022 - 10/2017
2	Fatigue 01/2022 - 09/2014
2	Actinic Keratosis 07/2014 - 03/2014
2	Warts (Wart) 07/2014 - 03/2014
2	Sarcoma (Soft Tissue Sarcoma) 11/2013 - 02/2013
1	Hypotension (Low Blood Pressure) 12/2023
1	Pruritus (Itching) 12/2023
1	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2022
1	Anemia 01/2022
1	Edema (Dropsy) 01/2022
1	Cutaneous Malignant Melanoma 01/2021
1	Merkel Cell Carcinoma 10/2019
1	Panniculitis 01/2018

Drug/Important Bio-Agent (IBA)

18	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 04/2012
15	VemurafenibIBA 01/2019 - 08/2010
12	dabrafenibIBA 08/2016 - 05/2012
11	Dacarbazine (DIC)FDA LinkGeneric 12/2023 - 08/2009
10	trametinibIBA 08/2016 - 08/2012
7	AZD 6244IBA 10/2017 - 04/2012
6	Temozolomide (Temodar)FDA LinkGeneric 10/2017 - 06/2009
5	IpilimumabIBA 12/2023 - 01/2017
5	Paclitaxel (Taxol)FDA LinkGeneric 01/2019 - 08/2009
5	Imatinib Mesylate (Gleevec)FDA Link 09/2014 - 04/2006
5	Proto-Oncogene Proteins B-rafIBA 05/2014 - 09/2010
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 12/2023 - 08/2012
4	Interleukin-2 (IL2)IBA 01/2023 - 02/2011
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2012
4	InterferonsIBA 11/2020 - 02/2011
4	temsirolimus FDA Link 10/2017 - 02/2012
4	Docetaxel (Taxotere)FDA Link 01/2017 - 06/2009
4	Cisplatin (Platino)FDA LinkGeneric 08/2014 - 06/2009
4	Phosphotransferases (Kinase)IBA 04/2014 - 04/2006
3	Immune Checkpoint InhibitorsIBA 01/2023 - 11/2020
3	Mitogen-Activated Protein KinasesIBA 01/2022 - 04/2013
3	Biomarkers (Surrogate Marker)IBA 11/2020 - 11/2015
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2017 - 02/2013
3	DNA (Deoxyribonucleic Acid)IBA 09/2015 - 02/2015
2	pembrolizumabIBA 01/2024 - 12/2023
2	Glycoproteins (Glycoprotein)IBA 12/2023 - 11/2014
2	NivolumabIBA 02/2022 - 01/2021
2	CytokinesIBA 11/2020 - 11/2015
2	Antineoplastic Agents (Antineoplastics)IBA 01/2020 - 05/2013
2	talimogene laherparepvecIBA 10/2019 - 11/2015
2	Carboplatin (JM8)FDA LinkGeneric 01/2019 - 01/2012
2	130-nm albumin-bound paclitaxelIBA 11/2018 - 08/2014
2	lenvatinibIBA 12/2015 - 11/2015
2	Immunoglobulins (Immunoglobulin)IBA 11/2015 - 11/2014
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 09/2014 - 08/2009
2	AlbuminsIBA 08/2014 - 12/2011
2	Sorafenib (BAY 43-9006)FDA Link 03/2014 - 02/2012
2	ErbB Receptors (EGF Receptor)IBA 03/2014 - 08/2011
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 03/2014 - 04/2006
2	Protein Kinases (Protein Kinase)IBA 10/2013 - 09/2010
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 02/2013 - 12/2011
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 02/2012 - 08/2010
2	Vincristine (Oncovin)FDA LinkGeneric 08/2011 - 12/2008
2	Liposomes (Liposome)IBA 08/2011 - 12/2008
2	docosahexaenoyl-paclitaxelIBA 12/2010 - 08/2009
1	2- amino- 1- methyl- 6- phenylimidazo(4,5- b)pyridineIBA 04/2024
1	Messenger RNA (mRNA)IBA 01/2024
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2023
1	HLA-A Antigens (HLA-A)IBA 12/2023
1	tebentafuspIBA 12/2023
1	Yttrium-90IBA 02/2022
1	CateninsIBA 01/2022
1	beta CateninIBA 01/2022
1	cobimetinibIBA 01/2022
1	binimetinibIBA 01/2022
1	ribociclibIBA 01/2022
1	bromosporineIBA 01/2022
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2022
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2021
1	Drug CombinationsIBA 01/2020
1	CreatinineIBA 01/2019
1	technetium-diethylenetriaminepentaacetic acid-mannosyl-dextranIBA 10/2018
1	AntibodiesIBA 01/2018

Therapy/Procedure

58	Therapeutics 04/2024 - 04/2004
10	Drug Therapy (Chemotherapy) 11/2018 - 08/2009
8	Immunotherapy 01/2023 - 02/2013
3	Radiotherapy 01/2018 - 12/2004
2	Craniotomy 01/2022 - 01/2018
2	Gamma Cameras (Gamma Camera) 12/2019 - 10/2018
1	Drug Tapering 02/2022
1	Microspheres (Microsphere) 02/2022
1	Neoadjuvant Therapy 01/2022